Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29588465 | 1.00 | LMNA (0.61) | LMNAMAPTPDK2PDK4CHRM2 | |
| SCHEMBL2715686 | 0.76 | LMNA (1.00) | LMNAMAPTPDK2PDK4CHRM2 | |
| SCHEMBL318947 | 0.75 | PDK2 (0.57) | LMNAMAPTPDK2PDK4CHRM2 | |
| SCHEMBL29651321 | 0.75 | PDK2 (0.57) | LMNAMAPTPDK2PDK4CHRM2 | |
| SCHEMBL31306897 | 0.73 | KMT2A (0.66) | LMNAPDK2PDK4CHRM2ADORA3 | |
| SCHEMBL18197230 | 0.73 | LMNA (0.61) | LMNAMAPTPDK2PDK4CHRM2 | |
| SCHEMBL4548022 | 0.73 | LMNA (0.61) | LMNAMAPTPDK2PDK4CHRM2 | |
| SCHEMBL18552443 | 0.73 | KMT2A (0.66) | LMNAPDK2PDK4CHRM2ADORA3 | |
| SCHEMBL18025761 | 0.73 | KMT2A (0.66) | LMNAPDK2PDK4CHRM2ADORA3 | |
| SCHEMBL209276 | 0.73 | KMT2A (0.66) | LMNAPDK2PDK4CHRM2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855829-B2 | 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-15 | — | — | US | disclosed |
| EP-1441722-A2 | MODULATORS OF KCNQ POTASSIUM CHANNELS AND USE THEREOF IN TREATING MIGRAINE AND MECHANISTICALLY RELATED DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-1363624-A2 | FLUORO OXINDOLE DERIVATIVES AS MODULATORS OF KCNQ POTASSIUM CHANNELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| EP-1363624-A2 | FLUORO OXINDOLE DERIVATIVES AS MODULATORS OF KCNQ POTASSIUM CHANNELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002066426-A3 | FLUORO OXINDOLE DERIVATIVES AS MODULATORS OF KCNQ POTASSIUM CHANNELS | BRISTOL MYERS SQUIBB CO (US) | 2002-11-21 | — | — | WO | disclosed |
| US-20020156120-A1 | Fluoro oxindole derivatives as modulators of KCNQ potassium channels | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-24 | — | — | US | disclosed |
| US-20020156120-A1 | Fluoro oxindole derivatives as modulators of KCNQ potassium channels | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-24 | — | — | US | disclosed |
| US-6469042-B1 | ANALGESICS FOR MIGRAINES | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-22 | — | — | US | disclosed |
| US-6469042-B1 | ANALGESICS FOR MIGRAINES | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-22 | — | — | US | disclosed |
| WO-2002072088-A2 | MODULATORS OF KCNQ POTASSIUM CHANNELS AND USE THEREOF IN TREATING MIGRAINE AND MECHANISTICALLY RELATED DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20020128277-A1 | Modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related diseases | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-12 | — | — | US | disclosed |
| WO-2002066426-A2 | FLUORO OXINDOLE DERIVATIVES AS MODULATORS OF KCNQ POTASSIUM CHANNELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002066426-A2 | FLUORO OXINDOLE DERIVATIVES AS MODULATORS OF KCNQ POTASSIUM CHANNELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128277-A1 | Modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related diseases | KCNQ5, KCNQ2, KCNQ1 | LMNA 2397/4885MAPT 3035/4885PDK2 1842/4885 |
| US-20020156120-A1 | Fluoro oxindole derivatives as modulators of KCNQ potassium channels | KCNQ1, KCNQ2, KCNQ3 | LMNA 3724/4885MAPT 4514/4885PDK2 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.